Cyclooxygenase-2 mediates gefitinib resistance in non-small cell lung cancer through the EGFR/PI3K/AKT axis

Gefitinib is a potent inhibitor of EGFR and represents the front-line treatment for non-small cell lung cancer (NSCLC) therapeutics. However, NSCLC patients are prone to develop acquired resistance through as yet, undefined mechanisms of resistance. Here, we investigated the role of COX-2 during gef...

Descripción completa

Detalles Bibliográficos
Autores principales: Deng, Qin-fang, Fang, Qi-yu, Ji, Xian-Xiu, Zhou, Song-wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Ivyspring International Publisher 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150449/
https://www.ncbi.nlm.nih.gov/pubmed/32284763
http://dx.doi.org/10.7150/jca.42850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7150449/
https://www.ncbi.nlm.nih.gov/pubmed/32284763
http://dx.doi.org/10.7150/jca.42850

Ejemplares similares